Open AccessEffect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
Author(s) -
David W. Dodick,
Stephen D. Silberstein,
Marcelo E. Bigal,
Paul Yeung,
Peter J. Goadsby,
Tricia Blankenbiller,
Melissa GrozinskiWolff,
Ronghua Yang,
Yuju Ma,
Ernesto Aycardi
Publication year - 2018
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2018.4853
Subject(s) - medicine , migraine , placebo , dosing , regimen , randomized controlled trial , tolerability , clinical endpoint , adverse effect , alternative medicine , pathology
Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom